ArticleJournal of natural products2023
Identification of Natural Products Inhibiting SARS-CoV-2 by Targeting Viral Proteases: A Combined in Silico and in Vitro Approach.
Article in Journal of natural products, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 33 citations in OpenAlex.
- How does NMR support SARS-CoV-2 protein-ligand interaction studies?Analytical and bioanalytical chemistry · 2026Review
- Biodiversity to Breakthroughs: The Promise of Saudi Arabian Medicinal Plants in Antiviral Research.Applied biochemistry and biotechnology · 2025Review
- Isolation and In Vitro Activity of Sesquiterpene Lactones fromMolecules (Basel, Switzerland) · 2025Article
- Kaurenoic acid is a potent inhibitor of SARS-CoV-2 RNA synthesis, virion assembly, and releaseFrontiers in microbiology · 2025Article
- Biopharmaceutical profiling of anti-infective sanggenons fromInternational journal of pharmaceutics: X · 2024Article
- Review
- Comprehensive overview of different medicinal parts fromFrontiers in pharmacology · 2024Review
- A study on the effect of natural products against the transmission of B.1.1.529 Omicron.Virology journal · 2023Review
- Protease inhibitors fromHeliyon · 2023Article
- Discovery of anti-SARS-CoV-2 secondary metabolites from the heartwood ofFrontiers in molecular biosciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, an integrated in silico-in vitro approach was employed to discover natural products (NPs) active against SARS-CoV-2. The two SARS-CoV-2 viral proteases, i.e., main protease (M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.